{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:14Z","timestamp":1789587014750,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.lfs.2025.123845","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T10:29:27Z","timestamp":1751797767000},"page":"123845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characterization of 0839 \u2013 A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide"],"prefix":"10.1016","volume":"378","author":[{"given":"Sanaz","family":"Gabery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Glendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ballarin-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Raun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Ehrenreich","family":"Kuhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2025.123845_bb0005","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.lfs.2025.123845_bb0010","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123845_bb0015","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123845_bb0020","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/oby.23374","article-title":"Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss","volume":"30","author":"Christoffersen","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.lfs.2025.123845_bb0025","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2025.123845_bb0030","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123845_bb0035","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123845_bb0040","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123845_bb0045","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2025.123845_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lfs.2025.123845_bb0055","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2025.123845_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-57724-5","article-title":"Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis","volume":"14","author":"Pipek","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.123845_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123845_bb0070","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123845_bb0075","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.lfs.2025.123845_bb0080","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2025.123845_bb0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2025.123845_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.105965","article-title":"Creating the amylin story","volume":"172","author":"Lutz","year":"2022","journal-title":"Appetite"},{"key":"10.1016\/j.lfs.2025.123845_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101109","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","volume":"46","author":"Sonne","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.lfs.2025.123845_bb0100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","article-title":"Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes","volume":"15","author":"Gutgesell","year":"2024","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.lfs.2025.123845_bb0105","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2025.123845_bb0110","author":"Press-release"},{"key":"10.1016\/j.lfs.2025.123845_bb0115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/ijp.ijp_860_22","article-title":"Translational research: bridging the gap between preclinical and clinical research","volume":"54","author":"Mahalmani","year":"2022","journal-title":"Indian J. Pharm."},{"key":"10.1016\/j.lfs.2025.123845_bb0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.lfs.2025.123845_bb0125","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2025.123845_bb0130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/oby.23626","article-title":"Poster abstracts","volume":"30","author":"Secher","year":"2022","journal-title":"Obesity"},{"key":"10.1016\/j.lfs.2025.123845_bb0135","first-page":"1","article-title":"CagriSema driven weight loss in diet-induced obese rats prevents counter-regulation of weight loss associated reduction in energy expenditure","volume":"67","author":"Kuhre","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2025.123845_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32009","article-title":"Improved leptin sensitivity and increased soluble leptin receptor concentrations may underlie the additive effects of combining PYY [3\u201336] and exendin-4 on body weight lowering in diet-induced obese mice","volume":"10","author":"Wulff","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.lfs.2025.123845_bb0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","article-title":"Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2025.123845_bb0150","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1023\/A:1011935603893","article-title":"How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study","volume":"46","author":"Willems","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.lfs.2025.123845_bb0155","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.lfs.2025.123845_bb0160","series-title":"A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight","year":"2024"},{"key":"10.1016\/j.lfs.2025.123845_bb0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/bbrc.1998.9308","article-title":"Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin)","volume":"250","author":"Gebre-Medhin","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2025.123845_bb0170","article-title":"A cross-species atlas of the dorsal vagal complex reveals neural mediators of Cagrilintide's effects on energy balance","author":"Ludwig","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.lfs.2025.123845_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? \u2013 comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2025.123845_bb0185","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s41593-020-0684-9","article-title":"High-fat food biases hypothalamic and mesolimbic expression of consummatory drives","volume":"23","author":"Mazzone","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.lfs.2025.123845_bb0190","first-page":"R1025","article-title":"Dietary obesity in nine inbred mouse strains","volume":"262","author":"West","year":"1992","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.lfs.2025.123845_bb0195","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/oby.20811","article-title":"Variations in body weight, food intake and body composition after long-term high-fat diet feeding in C57BL\/6J mice","volume":"22","author":"Yang","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.lfs.2025.123845_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246569","article-title":"The feeding microstructure of male and female mice","volume":"16","author":"Rathod","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2025.123845_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114501","article-title":"Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans","volume":"43","author":"Jacobsen","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.lfs.2025.123845_bb3000","unstructured":"W. Timothy Garvey, Matthias Bl\u00fcher, Cynthia Karenina Osorto Contreras, Melanie J. Davies, Eva Winning Lehmann, Kirsi H. Pietil\u00e4inen, Domenica Rubino, Paolo Sbraccia, Thomas Wadden, Niels Zeuthen, John P.H. Wilding, Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 0, 0, (undefined)."},{"key":"10.1016\/j.lfs.2025.123845_bb3005","unstructured":"Melanie J. Davies, Harpreet S. Bajaj, Christa Broholm, Astrid Eliasen, W. Timothy Garvey, Carel W. le Roux, Ildiko Lingvay, Christian B\u00f8ge Lyndgaard, Julio Rosenstock, Sue D. Pedersen, Cagrilintide\u2013Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes, New England Journal of Medicine, 0, 0, (undefined)."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525004801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525004801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:49:18Z","timestamp":1773294558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320525004801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":42,"alternative-id":["S0024320525004801"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123845","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of 0839 \u2013 A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"123845"}}